1. Background {#sec132621}
=============

Recent studies have demonstrated the increasing incidence of papillary thyroid carcinoma all over the world; papillary thyroid carcinoma (PTC) is the most common malignancy in four main types of thyroid cancers, accounting for 80% of human thyroid cancers ([@A20960R1], [@A20960R2]). It has been described in details that microRNAs (miRNAs) are potential biomarkers in papillary thyroid carcinogenesis ([@A20960R3]). According to our recent study, hsa-miR-222, hsa-miR-15a and their putative target gene, Axis inhibition protein 2 (AXIN2), were described to be associated with PTC ([@A20960R4]). The *AXIN2* gene is a negative regulator gene of Wnt/β-catenin signaling pathway and it is a putative tumor suppressor gene in a negative feedback loop that limits the duration and intensity of Wnt-initiated signals ([@A20960R5], [@A20960R6]). This preliminary result leads us to question whether *AXIN2* is involved in the development of papillary thyroid carcinoma.

2. Objectives {#sec132622}
=============

The purpose of this study was to explore the association between *AXIN2* gene polymorphism and PTC.

3. Patients and Methods {#sec132623}
=======================

We analyzed 106 samples collected from China-Japan Union Hospital in Jilin province, China during October 2010 to March 2011. The case group included all patients with confirmed clinical pathological diagnosis of thyroid papillary carcinoma during October 2010 to March 2011 in hospitals and their diagnosis was confirmed by two doctors at the same time. The control group included people who had physical examinations at the hospital during October 2010 to March 2011, and had normal thyroid confirmed by eight thyroid function tests (free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), three iodine in serum thyroid nitric acid (TT3), total serum thyroxine (TT4), thyroid peroxidase antibody (TPOAb), thyrotropin receptor antibodies (TRAb), and thyroglobulin (Tg)) and the thyroid gland color Doppler ultrasound examination. Furthermore, individuals of the control group were those without other endocrine diseases and positive family history of thyroid disease and were age and sex matched with the patients group. Our study was examined and approved by the medical ethics committee of school of public health of Jilin University during September 2010 (code: 2010-09-03). We genotyped seven tagSNPs of *AXIN2* in the Chinese population. The tagSNPs were predicted using the Haploview 4.2 with Hapmap data (CHB, MAF \> 0.1, r^2^ \> 0.8), covering 100% of the SNPs. We used a case-control design to examine the association between *AXIN2* and PTC. All subjects were from the North China Han population. Blood samples were drawn from 56 patients (45 females and 11 males; average age of 45.13 ± 10.97) and 50 healthy controls (38 females and 12 males; average age of 41.9 ± 10.22).

Genomic DNA of all subjects was extracted from the whole blood sample using the Promega liquid extraction and purification of DNA Kit (Promega, USA). The genotyping analysis of the tagSNPs was done using the mechanism of assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) of MassARRAY platform (Sequenom, USA). At the same time, 20% of the total sample was extracted by the random sampling method and used in duplicate detection by the blind method.

The goodness-of-fit chi-square test was used to test deviations of the patients and controls from the Hardy-Weinberg equilibrium (HWE). Data were analyzed using the SPSS 16.0 program for windows (SPSS Inc. Chicago, IL, USA). The difference in the allele frequencies and genotype frequencies between cases and controls were analyzed using the R × C column contingency table χ^2^ test. The possible association of haplotypes constructed by the combined effects of two or more loci with PTC was analyzed through the UNPHASED 3.1.4 program.

4. Results {#sec132624}
==========

There was no statistically significant difference in the sex distributions (χ^2^ = 0.245, P = 0.621) of the two groups. All studied SNPs in both the patient and control group had a HWE (P \> 0.05). Results of single locus association analysis are shown in [Table 1](#tbl34222){ref-type="table"}. TagSNPs rs11655966, rs3923086, and rs7591 of *AXIN2* showed significant associations with PTC (P \< 0.05). The result of haplotypes analysis showed that rs11655966-rs3923086-rs4791169 had statistically significant differences between the two groups (P \< 0.05). Among the five possible combinations of this haplotype (A-G-G, A-T-A, A-T-G, T-T-A, and T-T-G) T-T-G showed significant differences (frequency of cases = 36 (33.96%), frequency of controls = 17.45 (18.56%), OR = 4.126, χ^2^ = 6.72, P = 0.009536) after 1000 permutations.

###### The Association Between Single Nucleotide Polymorphisms and Papillary Thyroid Carcinoma

  SNP              N    Allelic Frequency ^[a](#fn36242){ref-type="table-fn"}^, %   χ^2^   P       OR (95% CI)                                  Genotypic Frequency ^[a](#fn36242){ref-type="table-fn"}^, %   χ^2^   P                 
  ---------------- ---- ----------------------------------------------------------- ------ ------- -------------------------------------------- ------------------------------------------------------------- ------ ---- ---- ------- -------
  **rs11655966**                                                                                                                                                                                                                       
  Case group       54   70                                                          38     6.029   0.014 ^[b](#fn36243){ref-type="table-fn"}^   0.493 (0.280 - 0.870)                                         24     22   8    4.877   0.087
  Control group    48   47                                                          49     NA      NA                                           NA                                                            12     23   13   NA      NA
  **rs2240308**                                                                                                                                                                                                                        
  Case group       53   78                                                          28     2.885   0.089                                        0.597 (0.329 - 1.085)                                         27     24   2    3.327   0.190
  Control group    50   63                                                          37     NA      NA                                           NA                                                            17     29   4    NA      NA
  **rs3923086**                                                                                                                                                                                                                        
  Case group       55   102                                                         8      4.518   0.034 ^[b](#fn36243){ref-type="table-fn"}^   0.391 (0.161 - 0.950)                                         47     8    0    4.990   0.082
  Control group    50   83                                                          17     NA      NA                                           NA                                                            34     15   1    NA      NA
  **rs4074947**                                                                                                                                                                                                                        
  Case group       56   64                                                          48     0.161   0.689                                        0.894 (0.515 \~ 1.549)                                        19     26   11   0.242   0.886
  Control group    50   60                                                          40     NA      NA                                           NA                                                            18     24   8    NA      NA
  **rs4791169**                                                                                                                                                                                                                        
  Case group       56   79                                                          33     0.323   0.570                                        0.844 (0.470 - 1.515)                                         29     21   6    0.715   0.699
  Control group    49   65                                                          33     NA      NA                                           NA                                                            24     17   8    NA      NA
  **rs7210356**                                                                                                                                                                                                                        
  Case group       55   96                                                          14     0.000   0.994                                        0.997 (0.444 \~ 2.239)                                        42     12   1    0.636   0.727
  Control group    50   87                                                          13     NA      NA                                           NA                                                            39     9    2    NA      NA
  **rs7591**                                                                                                                                                                                                                           
  Case group       55   81                                                          29     4.674   0.031 ^[b](#fn36243){ref-type="table-fn"}^   0.525 (0.292 - 0.945)                                         29     23   3    4.687   0.096
  Control group    50   60                                                          40     NA      NA                                           NA                                                            17     26   7    NA      NA

Abbreviation: NA, not available; SNP, single nucleotide polymorphisms.

^a^Note: 1 wild allele, 2 mutational allele; 1/1 homozygous wild genotype, 1/2 heterozygous genotype, 2/2 homozygous mutational genotype.

^b^P \< 0.05.

5. Discussion {#sec132625}
=============

To our knowledge, this was the first study to find an association between *AXIN2* polymorphisms and PTC in the Chinese population. In the present study, we identified seven tagSNPs on *AXIN2*, among them, rs2240308 belonged to the non-synonymous region, rs7591 was located on 3'untranslated regions (3'UTRs) and other sites were located in the intron. There was no significant difference shown in the distribution of the genotype loci through the statistical analysis of the case and the control group (P \> 0.05); prompting rs11655966, rs3923086 and rs7591 were independently associated with PTC susceptibility. However, the result of haplotypes showed statistical significance. Taking into consideration the above findings, we further concluded that *AXIN2* is likely relevant in genetic susceptibility to PTC.

*AXIN2* is located on chromosome 17q23-24, its cDNA is about 2.5 KB in length, consisting of 10 exons, coding AXIN-2α (843 amino acids) and AXIN-2β (778 amino acids) ([@A20960R7]). *AXIN2* gene is involved in embryonic development, tumor formation, programmed cell death, glycogen metabolism and other physiological and pathological processes, and plays an important role in the Wnt signaling pathways, stress activated protein kinase (SAPK) signaling pathway, transforming growth factors (TGF)--β signaling pathways and insulin signal transduction pathway ([@A20960R8]). *AXIN2* has relationships with colorectal cancer, lung cancer, adrenal cortical tumors, medulloblastomas, astrocytoma, hepatoblastoma, autosomal dominant ectodermal dysplasia and neoplastic syndrome, yet its association with prostate cancer has not yet been found ([@A20960R9]).

However, there are many uncontrollable confounding factors in this case-control study, which may lead to bias in the results. According to the above reason, we strictly followed the inclusion criteria of the case and control group when we selected the study subjects, especially when screening thyroid papillary carcinoma in the control group.

Owing to the limited number of samples in our study, further research is recommended to further validate the accuracy and specificity of the association between *AXIN2* and PTC. Our findings can provide data for better understanding of the genetic and molecular pathogenesis of PTC. In the future, studies with larger samples and different ethnic groups are required. Such studies should enhance the efficiency of the statistical analysis and increase the number of SNPs that are to be detected. Moreover, learning the molecular mechanisms of *AXIN2* in PTC is fundamentally important in developing new molecular markers for earlier diagnosis and novel therapeutic targets.
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